|View printer-friendly version|
Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
March 7, 2018 at 8:00 AM EST
Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs
“Multiple myeloma is the second most common blood cancer in the US and
remains an incurable disease despite recent medical advances. Patients
are in need of new targeted treatment options that increase durable
The phase 1 study is a multicenter open-label dose-escalation trial designed to enroll approximately 75 patients with relapsed or refractory MM. SGN-CD48A will be administered at an initial dosing interval of every three weeks. The primary objectives of the trial are to evaluate the safety and tolerability of SGN-CD48A and to identify the maximum tolerated dose (MTD). Key secondary objectives include assessing the antitumor activity and identifying the recommended single-agent dose and schedule.
For more information about the phase 1 clinical trial (NCT03379584), please visit www.clinicaltrials.gov.
About Multiple Myeloma
Multiple myeloma (MM) is a rare and aggressive cancer that forms in
white blood cells called plasma cells. Cancerous plasma cells can crowd
out healthy blood cells, impair bone strength and weaken the immune
system. MM is the second most common blood cancer in the US. According
SGN-CD48A is a novel investigational ADC targeted to CD48, a cell surface protein highly expressed in multiple myeloma. The ADC uses Seattle Genetics’ latest technology innovation, a next generation PEGylated glucuronide linker that enables conjugation of eight molecules of the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) to a CD48-targeted monoclonal antibody. SGN-CD48A is designed to be highly stable in circulation and release an increased amount of MMAE upon internalization into CD48-expressing cells, producing greater antitumor activity in preclinical studies.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the therapeutic
potential of SGN-CD48A and its possible benefits and uses as
monotherapy, and anticipated clinical trial, patient enrollment target,
and intended endpoints. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
inability of SGN-CD48A to show sufficient activity in the clinical
setting referenced above and the risk of adverse events of SGN-CD48A.
More information about the risks and uncertainties faced by